Lv31
220 积分 2023-12-08 加入
Cadonilimab plus platinum-based chemotherapy with or without bevacizumab as first-line treatment for persistent, recurrent, or metastatic cervical cancer (COMPASSION-16): a randomised, double-blind, placebo-controlled phase 3 trial in China
1个月前
已完结
Multiple myeloma
2个月前
已完结
Phase II Study of Bevacizumab Plus Temozolomide During and After Radiation Therapy for Patients With Newly Diagnosed Glioblastoma Multiforme
3个月前
已关闭
Unlocking Hope: Anti-VEGFR inhibitors and their potential in glioblastoma treatment
3个月前
已完结
Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study
3个月前
已完结
Belzutifan versus Everolimus for Advanced Renal-Cell Carcinoma
4个月前
已完结
Renal cell carcinoma
5个月前
已完结
Resistance Mechanisms to Anti-PD Cancer Immunotherapy
5个月前
已完结
Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma
5个月前
已关闭
Atezolizumab plus cabozantinib versus cabozantinib monotherapy for patients with renal cell carcinoma after progression with previous immune checkpoint inhibitor treatment (CONTACT-03): a multicentre, randomised, open-label, phase 3 trial
6个月前
已完结
皖公网安备34019202002308
